GRI Bio GRI 深沪

等待开盘 06-24 09:30:00 美东时间

1.86

-0.010

-0.53%

华盛通

立即下载

最高1.8864
今开1.85
成交量 4.98万股
最低 1.72
昨收 1.87
总市值 329.38万
52周最高 80.36
市盈率 ^静 --
换手率 2.81%
52周最低 1.72
委比 -78.09%
总股本 177.08万
历史最高 64792072.80
量比 0.18
振幅 8.90%
历史最低 1.72
每手 1
风险率 22.96%

个股概要

财务分析

公司资料

分红派息

分时图
日k
周k
月k

相关新闻

GRI Bio Says FDA Grants Orphan Drug Designation To GRI-0621 For Treatment Of Idiopathic Pulmonary Fibrosis, Irreversible And Ultimately Fatal Lung Disease

Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity LA JOLLA, CA, June 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ:GRI) ("GRI Bio" or the "Company"), a biotechnology company developing innovative therapies for infl...

06-18 20:34
GRI Bio wins FDA orphan drug designation for GRI-0621 in pulmonary fibrosis

GRI Bio wins FDA orphan drug designation for GRI-0621 in pulmonary fibrosis FDA granted orphan drug designation to GRI-0621 (tazarotene) for idiopathic pulmonary fibrosis. Designation could support 7 years of US market exclusivity if the drug wins approval. GRI-0621 is a once-daily oral RARβ/γ-selec

06-18 20:31
美股大行评级 | 瑞杰金融上调美光目标价从530美元升至1100美元；AMD、Arm、戴尔、英特尔等获多家机构上调目标价

今日重点评级关注：Ascendiant Capital：维持RenovoRx"买入"评级，目标价从13.5美元升至14美元；BTIG：维持Jade Biosciences"买入"评级，目标价从39美元升至74美元

06-02 16:25
Dell Technologies To Gain Nearly 79%? Here Are 10 Analyst Calls Investors Should Know

Wall Street analysts updated views on notable stocks. See changes on analyst ratings page. Price targets raised/cut, ratings maintained/changed.

06-01 20:43
Ascendiant Capital Maintains Buy on GRI Bio, Lowers Price Target to $32

Ascendiant Capital analyst Edward Woo maintains GRI Bio (NASDAQ:GRI) with a Buy and lowers the price target from $40 to $32.

06-01 18:28
GRI Bio to Present at A.G.P.’s Annual Healthcare Company Showcase

GRI Bio, Inc. announced that its CEO, Marc Hertz, PhD, will participate in a fireside chat at A.G.P.’s Annual Healthcare Company Showcase on May 20, 2026. The event will discuss the company’s immune-modulating pipeline targeting inflammatory, fibrotic, and autoimmune diseases, including its lead program, GRI-0621, for idiopathic pulmonary fibrosis. A live webcast will be available on the company’s website.

05-18 13:15
GRI Bio发布Q1财报特发性肺纤维化新药数据积极

　　财务表现：亏损收窄，现金储备增强　　GRI Bio近日公布2026年第一季度财务报告。数据显示，公司一季度净亏损约200万美元，较上年同期的300万美元亏...

05-15 02:50
GRI Bio reports Q1 results

GRI Bio press release (GRI): Q1 Net loss for the quarter ended March 31, 2026, was approximately $2.0 million, compared to approximately $3.0 million for the same period in 2025 Cash and cash equivale...

05-15 02:31
GRI Bio Q1 EPS $(1.61) Misses $(0.91) Estimate

GRI Bio (NASDAQ:GRI) reported quarterly losses of $(1.61) per share which missed the analyst consensus estimate of $(0.91) by 78.89 percent. This is a 99.01 percent increase over losses of $(162.40) per share from the

05-14 20:45
GRI Bio Q1 net loss narrows on lower R&D expenses

GRI Bio Q1 net loss narrows on lower R&D expenses Overview U.S. biotechnology firm's Q1 net loss narrowed yr/yr, driven by lower R&D expenses Company raised $6.8 mln through At The Market facility, boosting cash to $11 mln Outlook Company expects existing cash to fund operations into Q2 2027 Company

05-14 20:42

派息除权日	每股总股息	派息日期
2023-03-23	0.63	2023-03-28
2022-12-22	0.53	2022-12-29
2022-09-22	0.45	2022-09-29
2022-06-23	0.48	2022-06-30
2022-03-24	0.52	2022-03-31
2021-12-22	0.56	2021-12-29
2021-09-23	0.44	2021-09-30
2021-06-17	0.47	2021-06-24
2021-03-18	0.51	2021-03-25
2020-12-22	0.64	2020-12-30
2020-09-17	0.35	2020-09-24
2020-06-18	0.42	2020-06-25
2020-03-19	0.68	2020-03-26
2019-12-19	0.51	2019-12-27
2019-09-19	0.27	2019-09-26
2019-06-20	0.37	2019-06-27
2019-03-21	0.35	2019-03-28
2018-12-20	0.41	2018-12-27
2018-09-20	0.22	2018-09-27
2018-06-21	0.44	2018-06-28
2018-03-22	0.22	2018-03-29
2017-12-21	0.95	2017-12-28
2017-09-21	0.33	2017-09-27
2017-06-21	0.35	2017-06-28
2016-12-21	0.46	2016-12-29
2016-09-21	0.38	2016-09-28
2016-06-22	0.31	2016-06-29
2016-03-23	0.37	2016-03-31
2015-12-23	0.21	2015-12-31
2015-09-23	0.13	2015-09-30
2015-06-24	0.68	2015-07-01
2015-03-25	0.44	2015-04-01
2014-12-24	0.41	2015-01-02
2014-09-24	0.24	2014-10-01
2014-06-25	0.39	2014-07-02
2014-03-26	0.22	2014-04-02
2013-12-26	0.17	2014-01-03
2013-09-25	0.23	2013-10-02
2012-12-26	2.23	2013-01-03
2012-09-26	0.23	2012-10-03
2012-06-20	0.26	2012-06-27
2012-03-21	0.15	2012-03-28
2011-12-21	0.18	2011-12-28
2011-09-21	0.20	2011-09-28
2011-06-22	0.28	2011-06-29
2011-03-23	0.61	2011-03-30
2010-12-21	1.12	2010-12-29
2010-09-22	0.18	2010-09-29
2010-06-23	0.21	2010-06-30
2010-03-24	0.43	2010-03-31
2009-12-29	1.03	2010-01-06
2009-09-29	0.08	2009-10-06
2009-06-29	0.57	2009-07-07
2008-12-29	0.49	2009-01-05

公司名称	GRI Bio
行业分类	--
业务描述	GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

GRI Bio GRI 深 沪

1.86

个股概要

财务分析

公司资料

相关新闻

分红派息

相关新闻

公司简介

GRI Bio GRI 深沪